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MTT assayAbstract A novel series of 2-(3-(4-oxo-2-substituted phenyl thiazolidin-3-yl)phenyl)benzo[d]
thiazole-6-carboxylic acid derivatives PP1–PP8 were synthesized by various benzothiazole
Schiff’s bases by reaction with thioglycollic acid. Their structures were established on the basis
of IR, 1H-NMR, 13C-NMR, mass spectral data and elemental analysis. All the synthesized com-
pounds were screened for their in vitro anticancer activity by 3-(4,5-dimethyl thiazole-2yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay on human cervical cancer cell line (HeLa) cell lines.
Among these compound PP2 exhibited most signiﬁcant activity as compared with PP5, PP7
and PP8. However, the activity was less as compared to the standard drug Cisplatin.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Cancer is a serious worldwide health threat, killing almost se-
ven million people a year. The human cancer comprises more
than 200 different diseases together, they account for about
one-ﬁfth of all deaths worldwide. Numerous heterocyclic com-
pounds, which are the analogs of natural substances, may be
used as transporters for anticancer agents to cancer cells.
The benzothiazoles have been the target of many researches
for many years because they constitute an important class of
heterocyclic compounds exhibiting considerable chemothera-
peutic activities. Benzothiazole and its bioisosteres, benzoxazole
SN
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Figure 1 General SAR of benzothiazole.
182 P.P. Prabhu et al.and benzimidazole, were studied for their antimicrobial,
(Wada et al., 1973; Akerfeldt, 1970), anticancer, antiinﬂamma-
tory, analgesic (Majo et al., 2003), antitubercular (Bhusari
et al., 2000), antiviral (Akerfeldt, 1970), antioxidant (Pus-
toshnaya et al., 2000), antifungal (Padmavathi et al., 2011),
anthelmintic (Udapaudi and Mahajanshetty, 1986), plant
growth regulator (Loos et al., 1999), antidiabetic (Pattan
et al., 2005) activities. In the last few years various substituted
benzothiazole derivatives were studied extensively for their
anticancer activity (Schnur et al., 1991; Hutchinson et al.,
2003). Several chlorinated (Bhargava, 1960) and ﬂuorinated
(Hutchinson et al., 2001) derivatives of this moiety exhibit
excellent in vitro as well as in vivo anticancer activities. In the
drug design, structure activity relationship study is an area
of research which assumes that differences in the structural
or physical properties measured experimentally account for
differences in the observed biological properties (Yoshida
et al., 2005; Nadkarni et al., 2000; Stevens et al., 1994; Alam
and Siddiqui, 2004) (Fig. 1). In the view of these observations,
some novel 2-phenyl thiaolidinone substituted-2-phenyl benzo-
thiazole-6-carboxylic acid derivatives have been synthesized
which have a –Cl, –F and –NO2 substitution attached on phe-
nyl ring in order to examine their in vitro anticancer activity.
Additionally, we also put an electron-donating group such as
–CH3, –OCH3, –OH to discuss the effect of substituent for bio-
logical activity.
2. Materials and methods
2.1. Materials
Synthetic starting material, reagents, and solvents were of ana-
lytical grade or of the highest quality commercially available.
The chemicals were purchased from Aldrich Chemical Co.,
and Merck Chemical Co., respectively, and were dried when-
ever necessary.
2.2. Instrumentation
The melting points were determined in open capillary tubes and
were uncorrected. Infrared (IR) spectra were recorded withKBr
pellets (ABBBomemFT-IR spectrometerMB 104ABB limited,
Bangaluru, India). Proton nuclear magnetic resonance
(1H-NMR) spectra (Bruker 400 NMR spectrometer, Mumbai,
India) were recorded with in CDCl3, tetramethylsilane (TMS;
d= 0.00 ppm) was served as internal standards for 1H-NMR.Chemical shifts were reported in ppm from tetramethylsilane
with the solvent resonance as the internal standard (CDCl3,
d= 7.26). Spectra are reported as follows: chemical shift (d
ppm), multiplicity (s = singlet, d = doublet, t = triplet, q =
quartet, m = multiplet, dd = doublet of doublet), coupling
constants (Hz), integration and assignment if any. 13C-NMR
spectra were collected on commercial instruments (100 MHz)
with complete proton decoupling. Mass spectra were measured
with Micromass Q-Tof (ESI Source, TOF), and microanalyses
were performed using a vario EL V300 elemental analyzer
(Analysensysteme GmbH, Chennai, India). The purity of the
compounds was checked by TLC on pre-coated SiO2 gel
(HF254, 200mesh) aluminum plates (E.Merck) using ethyl ace-
tate:petroleum ether (1:1) and visualized in a UV chamber. The
structure of newly synthesized compoundswas conﬁrmed by IR,
1H-NMR, 13C-NMR, mass spectra and elemental analysis.
2.3. General procedure
The reaction sequences employed for the synthesis of title com-
pounds are shown in Scheme 1. The Schiff’s bases of benzothi-
azole carboxylic acid derivatives were prepared according to
the previously described method (Padmavathi et al., 2011).
2.3.1. Synthesis of thiazolidinone substituted benzothiazole-6-
carboxylic derivatives (PP1–PP8)
The mixture of Schiff bases 1 (0.013 mol) treated with thiogly-
collic acid (0.016 mol) in dry benzene 40 mL was reﬂuxed for
6 h. Water formed during the reaction was removed azeotrop-
ically by Dean–Stark apparatus. Progress of the reaction was
checked by TLC using ethyl acetate:petroleum ether (2:8) as
eluent. After the completion of reaction, benzene was removed
by distillation to give solid, which was dissolved in methanol
(70 mL). This solution was warmed and treated with sodium
bicarbonate solution to remove unreacted acid. The solid ob-
tained was ﬁltered, washed with ether and puriﬁed by crystalli-
zation from methanol to give PP1. Similarly, other compounds
PP2–PP8 have been synthesized.
2.3.1.1. 2-(3-(4-Oxo-2-phenylthiazolidin-3-yl)phenyl)benzo[d]
thiazole-6-carboxylicacid (PP1). This compound was obtained
as a colorless crystals; Yield: 70%; mp: 251–253 C; IR (KBr,
cm1): 3026 (Ar-CH), 1720 (C‚O), 1524 (C‚C); 1H-NMR
(CDCl3): d 3.6–3.7 (dd, 2H, –SCH2, J= 12.4), d 6.6 (s, 1H,
–NCH), d 7.2–8.9 (m, 12H, Ar-H), d 10.6 (s, 1H, –COOH);
13C-NMR: d 35.6, 66.9, 120, 123.7, 125.0, 127.2, 127.6,
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Scheme 1 Synthesis of thiazolidinone substituted benzothiazole-6-carboxylic derivatives.
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167.7 and 173.3; HR-ESI-MS: Calculated for C23H16N2O3S2
(432.52474); Found 433.51310 (M+H); Anal. calcd for
C23H16N2O3S2; C, 63.87; H, 3.73; and N, 6.48; Found: C,
63.74; H, 3.65; and N, 6.33.
2.3.1.2. 2-(3-(2-(4-Chlorophenyl)-4-oxothiazolidin-3-yl) phe-
nyl) benzo[d]thiazole-6-carboxylic acid (PP2). This com-
pound was obtained as a light yellow crystals; Yield: 68%;
mp: 262–265 C; IR (KBr, cm1): 3025 (Ar-CH), 1680
(C‚O), 1525 (C‚C); 1H-NMR (CDCl3): d 3.6–3.7 (dd, 2H,
–SCH2, J= 12.4), 6.6 (s, 1H, –NCH,), d 7.2–8.9 (m, 11H,
Ar-H), 10.6 (s, 1H, –COOH); 13C-NMR: d 35.6, 66.9, 120,
123.7, 125.0, 127.2, 127.6, 128.0, 129.4, 131.4, 137.0, 137.3,
138.1, 140.5, 156.3, 162.5, 167.7, 173.3; HR-ESI-MS: Calcu-
lated for C23H15ClN2O3S2 (466.95980); Found 467.95870
(M+H); Anal. calcd for C23H15ClN2O3S2; C, 59.16; H, 3.24;
and N, 6.00; Found: C, 59.01; H, 3.20; and N, 5.98.
2.3.1.3. 2-(3-(2-(3-Fluorophenyl)-4-oxothiazolidin-3-yl)phe-
nyl) benzo[d]thiazole-6-carboxylic acid (PP3). This com-
pound was obtained as a light pale yellow crystals; Yield:
70%; mp: 270–273 C; IR (KBr, cm1): 3022 (Ar-CH), 1680
(C‚O), 1524 (C‚C); 1H-NMR (CDCl3): d 3.67–3.76 (dd,
2H, –SCH2, J= 12.4), d 6.7 (s, 1H, –NCH), d 6.9–8.9 (m,
11H, Ar-H), d 10.6 (s, 1H, –COOH); 13C-NMR: d 35.6, 67.0,
111.3, 111.6, 120.0, 122.5, 123.7, 125.0, 127.2, 127.6, 129.6,
131.4, 137.0, 137.3, 138.1, 140.5, 156.3161.9, 162.5, 164.5,
167.7, and 173.4; HR-ESI-MS: Calculated for C23H15FN2O3S2
(450.50520); Found 451.49920 (M+H); Anal. calcd for
C23H15FN2O3S2; C, 61.32; H, 3.36; and N, 6.22; Found: C,
61.02; H, 3.16; and N, 6.12.
2.3.1.4. 2-(3-(2-(4-Nitrophenyl)-4-oxothiazolidin-3-yl)phenyl)
benzo[d]thiazole-6-carboxylic acid (PP4). This compound
was obtained as a light orange crystals; Yield: 72%; mp:
275–278 C; IR (KBr, cm1): 3021 (Ar-CH), 1684 (C‚O),
1520 (C‚C); 1H-NMR (CDCl3): d 3.70–3.77 (dd, 2H, –
SCH2, J= 12.4), d 6.7 (s, 1H, –NCH,), d 7.4–8.9 (m, 11H,
Ar-H), d 10.6 (s, 1H, –COOH); 13C-NMR: d 35.6, 66.9, 120,
123.7, 125.0, 127.2, 127.6, 128.0, 129.4, 131.4, 137.0, 137.3,
138.1, 140.5, 156.3, 162.5, 167.7, and 173.3; HR-ESI-MS:Calculated for C23H15N3O5S2 (477.51230); Found 478.50210
(M+H); Anal. calcd for C23H15N3O5S2; C, 57.85; H, 3.17;
and N, 8.80; Found: C, 57.80; H, 3.15; and N, 8.71.
2.3.1.5. 2-(3-(2-(4-Methoxyphenyl)-4-oxothiazolidin-3-yl)phe-
nyl) benzo[d]thiazole-6-carboxylic acid (PP5). This com-
pound was obtained as colorless crystals; Yield: 70%; mp:
280–282 C; IR (KBr, cm1): 3025 (Ar-CH), 1690 (C‚O),
1522 (C‚C); 1H-NMR (CDCl3): d 3.70–3.79 (dd, 2H, –
SCH2, J= 12.4), d 3.79 (s, 3H, –OCH3), d 6.6 (s, 1H, –
NCH), d 6.8–8.9 (m, 11H, Ar-H), d 0.6 (s, 1H, –COOH);
13C-NMR: d 35.6, 56.0, 66.9, 114.3, 120.0, 123.7, 125.0,
127.2, 127.6, 128.0, 129.4, 131.4, 137.0, 137.3, 138.1, 140.5,
156.3160.8, 162.5, 167.7, and 173.4; HR-ESI-MS: Calculated
for C24H18N2O4S2 (462.54072); Found 485.32082 (M+Na);
Anal. calcd for C24H18N2O4S2; C, 62.32; H, 3.92; and N,
6.06; Found: C, 62.14; H, 3.86; and N, 5.96.
2.3.1.6. 2-(3-(2-(4-Fluoro-3-methoxyphenyl)-4-oxothiazolidin-
3-yl)phenyl)benzo[d ]thiazole-carboxylic acid (PP6). This
compound was obtained as a pale yellow crystals; Yield:
68%; mp: 310–312 C; IR (KBr, cm1): 3027 (Ar-CH), 1710
(C‚O), 1518 (C‚C); 1H-NMR (CDCl3): d 3.70–3.79 (dd,
2H, –SCH2, J= 12.4), 3.84 (s, 3H, –OCH3), 6.7 (s, 1H, –
NCH) 6.8–9.0 (m, 10H, Ar-H), 10.5 (s, 1H, –COOH); 13C-
NMR: d 35.6, 56.7, 67.0, 113.9, 116.5, 119.0, 120.0, 123.7,
125.0, 127.2, 127.6, 128.0, 129.4, 131.4, 137.0, 137.3, 138.1,
149.3, 140.5, 154.5156.3, 157.1, 162.5, 167.7, and 173.3; HR-
ESI-MS: Calculated for C24H17FN2O4S2 (480.53118); Found
481.52111 (M+H); Anal. calcd for C24H17FN2O4S2; C,
59.99; H, 3.57; and N, 5.83; Found: C, 59.85; H, 3.14; and
N, 5.13.
2.3.1.7. 2-(3-(4-Oxo-2-p-tolylthiazolidin-3-yl)phenyl)benzo[d]
thiazole-6-carboxylicacid (PP7). This compound was obtained
as a colorless crystals; Yield: 72%; mp: 266–269 C; IR (KBr,
cm1): 3028 (Ar-CH), 1711 (C‚O), 1519 (C‚C); 1H-NMR
(CDCl3): d 2.3 (s, 3H, –CH3), d 3.69–3.76 (dd, 2H, –SCH2,
J= 12.4), d 6.5 (s, 1H, –NCH), d 7.1–9.0 (m, 11H, Ar-H), d
10.54 (s, 1H, –COOH); 13C-NMR: d 21.1, 35.6, 66.9, 120.0,
123.7, 125.0, 126.3, 127.2, 127.6, 128.0, 129.4, 131.4, 137.0,
137.3, 137.8, 138.1, 139.0, 156.3, 162.5, 167.7, and 173.3;
Table 1 Results of in vitro anticancer activity of synthesized
compounds PP1–PP8.
Compd. Compound concentration (lmol/L) IC50
% Growth inhibition
5 12.5 25 40
PP1 0.6 3.2 10.2 15.6 >100
PP2 50.7 66.8 80.8 96.8 9.768
PP3 1.2 4.9 8.8 19.8 >100
PP4 5.15 6.2 4.56 18.58 >100
PP5 45.7 70.8 77.9 88.45 14.566
PP6 0.4 4.4 9.7 18.6 >100
PP7 40.8 66.7 70.7 82.68 16.456
PP8 44.9 68.8 76.9 81.7 17.768
Cisplatin 64.2 75.3 86.9 99.7 28.427
184 P.P. Prabhu et al.HR-ESI-MS: Calculated for C24H18N2O3S2 (446.54132);
Found 468.51011 (M+Na); Anal. calcd for C24H18N2O3S2;
C, 59.99; H, 3.57; and N, 5.83; Found: C, 59.85; H, 3.14;
and N, 5.13.
2.3.1.8. 2-(3-(2-(4-Hydroxyphenyl)-4-oxothiazolidin-3-yl)phe-
nyl) benzo[d]thiazole-6-carboxylic acid (PP8). This com-
pound was obtained as a colorless crystals; Yield: 72%; mp:
266–269 C; IR (KBr, cm1): 3025 (Ar-CH), 1705 (C‚O),
1516 (C‚C); 1H-NMR (CDCl3): d 3.5 (s, 1H, –OH), d 3.70–
3.78 (dd, 2H, –SCH2, J= 12.4), d 6.6 (s, 1H, –NCH), d 7.1–
9.0 (m, 11H, Ar-H), d 10.54 (s, 1H, –COOH); 13C-NMR: d
21.1,35.6, 66.9, 120.0, 123.7, 125.0, 126.3, 127.2, 127.6, 128.0,
129.4, 131.4, 137.0, 137.3, 137.8, 138.1, 139.0, 156.3, 162.5,
167.7, and 173.3; HR-ESI-MS: Calculated for C23H16N2O4S2
(448.51414); Found 449.51224 (M+H); Anal. calcd for
C23H16N2O4S2; C, 61.59; H, 3.60; and N, 6.25; Found: C,
61.29; H, 3.15; and N, 6.12.
3. Biological evaluation
3.1. In vitro anticancer screening
The mitochondrial synthesis was determined by MTT (Akhil
et al., 1999; Eisenbrand et al., 2002). The ability of the cells
to survive as a toxic insult has been the basis of most cytotox-
icity assays. This assay is based on the assumption that dead
cells or their products do not reduce tetrazolium. The assay
depends both on the number of cells present and on the living
cells is clearly a very effective principle on which the assay is
based. The principle involved is the cleavage of tetrazolium salt
into a blue colored product (formazan) by mitochondrial
enzyme succinate dehydrogenase. The number of live cells
was found to be proportional to the extent of formazan pro-
duction by the cells used. HeLa cell lines were used for antican-
cer activity. Cisplatin (1.25–15 lg/mL) is used as the standard.
The cytotoxicity effect was expressed as IC50, which was calcu-
lated by bliss.
4. Results and discussion
4.1. In vitro method
To gain further proof in favor of this hypothesis eight new 2(3-
(4-oxo-2-substituted phenyl thiazolidin-3-yl) phenyl)benzo
[d]thiazole-6-carboxylic acid derivatives were synthesized and
tested for in vitro anticancer activity. At the commencement
of this study in the screening, compound PP2 exhibited better
anticancer activity and showed 96.8% inhibition and 9.768,
IC50 value. The position was modiﬁed with differently substi-
tuted aromatic aldehydes such as p-Cl, m-F, p-NO2, p-
OCH3, p-F and m-OCH3, p-CH3 and p-OH benzaldehydes.
The promising nature of the compounds may be attributed
to the substitutions at the hydrophobic domain. These com-
pounds had electron withdrawing groups at the para position
of the hydrophobic aryl ring. In general it was observed that
the para substituted derivatives were more active than the
other derivatives. This may be because of the fact that the para
substituted derivatives are better ﬁtted into the receptor site.
The structural modiﬁcation resulted in the substantial
improvement in activity. Enhancement in activity indicatesthat this modiﬁcation is step up toward synthesis of a pharma-
cophore. The position of the substituted group on the phenyl
ring appeared to greatly inﬂuence the anticancer activity; the
p-Cl derivative PP2 exhibited higher anticancer activity than
the p-OCH3, p-CH3 and p-OH derivatives PP5, PP7 and
PP8. At the same p-position, compound with NO2 substitution
PP4 exhibited less anticancer activity followed by compound
with m-F substitution PP3, p-F and m-OCH3 substitution
PP6 and unsubstitution PP1. The anticancer activity screening
results of these compounds are shown in Table 1.
5. Conclusion
In the present investigation, for the ﬁrst time, we synthesized a
series of novel 2-(3-(4-oxo-2-substituted phenyl thiazolidin-3-
yl)phenyl)benzo[d]thiazole-6-carboxylic acid moieties and were
successfully tested by the effect of anticancer activities done on
MTT method. On correlating the structures of the sample can-
didate with their biological activity, it has been observed that
the eight phenyl substituted derivatives PP1–PP8, four com-
pounds PP2, PP5, PP7 and PP8 have selectivity toward HeLa
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